Immunotherapy as a later-line option for HER2-altered advanced non-small-cell lung cancer: taxane might be a favorable partner

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J. Clin. 72(1), 7–33 (2022).
  MedlineGoogle Scholar
• 2. Shigematsu H, Takahashi T, Nomura M et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 65(5), 1642–1646 (2005).
  Medline CASGoogle Scholar
• 3. Arcila ME, Chaft JE, Nafa K et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin. Cancer Res. 18(18), 4910–4918 (2012). • Large-scale study demonstrating HER2 mutations in lung cancer.
  Medline CASGoogle Scholar
• 4. Mazières J, Peters S, Lepage B et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J. Clin. Oncol. 31(16), 1997–2003 (2013).
  Medline CASGoogle Scholar
• 5. Friedlaender A, Subbiah V, Russo A et al. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nat. Rev. Clin. Oncol. 19(1), 51–69 (2022). •• Review of HER2 exon 20 insertion and treatment perspectives.
  Medline CASGoogle Scholar
• 6. Auliac J-B, Dô P, Bayle S et al. Non-small cell lung cancer patients harboring HER2 mutations: clinical characteristics and management in a real-life setting. Cohort HER2 EXPLORE GFPC 02-14. Adv. Ther. 36(8), 2161–2166 (2019).
  Medline CASGoogle Scholar
• 7. Zhou J, Ding N, Xu X et al. Clinical outcomes of patients with HER2-mutant advanced lung cancer: chemotherapies versus HER2-directed therapies. Ther. Adv. Med. Oncol. 12, 1758835920936090 (2020).
  Google Scholar
• 8. Eng J, Hsu M, Chaft JE, Kris MG, Arcila ME, Li BT. Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers. Lung Cancer 99, 53–56 (2016).
  MedlineGoogle Scholar
• 9. Mazières J. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann. Oncol. 27(2), 6 (2016).
  MedlineGoogle Scholar
• 10. Wang Y, Zhang S, Wu F et al. Outcomes of pemetrexed-based chemotherapies in HER2-mutant lung cancers. BMC Cancer 18(1), 326 (2018).
  MedlineGoogle Scholar
• 11. Xu F, Yang G, Xu H, Yang L, Qiu W, Wang Y. Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China. Thorac. Cancer 11(3), 679–685 (2020).
  Medline CASGoogle Scholar
• 12. Yang S, Wang Y, Zhao C et al. Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations. Transl. Lung Cancer Res. 10(2), 753–765 (2021).
  Medline CASGoogle Scholar
• 13. Lau SCM, Fares AF, Le LW et al. Subtypes of EGFR- and HER2-mutant metastatic NSCLC influence response to immune checkpoint inhibitors. Clin. Lung Cancer 22(4), 253–259 (2021).
  Medline CASGoogle Scholar
• 14. Lai W-CV, Feldman DL, Buonocore DJ et al. PD-L1 expression, tumor mutation burden and response to immune checkpoint blockade in patients with HER2-mutant lung cancers. J. Clin. Oncol. 36(Suppl. 15), 9060 (2018).
  Google Scholar
• 15. Takeda M, Sakai K, Hayashi H et al. Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2. Oncotarget 9(30), 21132–21140 (2018).
  MedlineGoogle Scholar
• 16. Mazieres J, Drilon A, Lusque A et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann. Oncol. 30(8), 1321–1328 (2019).
  Medline CASGoogle Scholar
• 17. Guisier F, Dubos-Arvis C, Viñas F et al. Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018. J. Thorac. Oncol. 15(4), 628–636 (2020).
  Medline CASGoogle Scholar
• 18. Chen K, Pan G, Cheng G et al. Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions. Thorac. Cancer 12(2), 218–226 (2021).
  Medline CASGoogle Scholar
• 19. Cinausero M, Laprovitera N, De Maglio G et al. KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. Ther. Adv. Med. Oncol. 11, 1758835919885540 (2019).
  Google Scholar
• 20. Yang G, Yang Y, Liu R et al. First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study. Ther. Adv. Med. Oncol. 14, 17588359221082340 (2022). • Large population-based real-world study identifying the role of immune checkpoint inhibitors (ICIs) in first-line treatment.
  Google Scholar
• 21. Saalfeld FC, Wenzel C, Christopoulos P et al. Efficacy of immune checkpoint inhibitors alone or in combination with chemotherapy in NSCLC harboring ERBB2 mutations. J. Thorac. Oncol. 16(11), 1952–1958 (2021). •• Evaluation of effectiveness of ICIs combined with chemotherapy.
  Medline CASGoogle Scholar
• 22. Zhu L, Chen L. Progress in research on paclitaxel and tumor immunotherapy. Cell. Mol. Biol. Lett. 24(1), 40 (2019).
  Medline CASGoogle Scholar
• 23. Paz-Ares L, Luft A, Vicente D et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379(21), 2040–2051 (2018).
  Medline CASGoogle Scholar
• 24. Schmid P, Adams S, Rugo HS et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379(22), 2108–2121 (2018).
  Medline CASGoogle Scholar
• 25. Zhang G-C, Liao N, Chen B et al. Next-generation sequencing (NGS) identifies a new breast cancer subtype with HER2 low-amplification status as a candidate for targeted therapy. J. Clin. Oncol. 38(Suppl. 15), 553 (2020).
  Google Scholar
• 26. Fang W, Zhao S, Liang Y et al. Mutation variants and co-mutations as genomic modifiers of response to afatinib in HER2-mutant lung adenocarcinoma. Oncologist 25(3), e545–e554 (2020).
  Medline CASGoogle Scholar
• 27. Bachelot T, Ciruelos E, Schneeweiss A et al. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann. Oncol. 30(5), 766–773 (2019).
  Medline CASGoogle Scholar
• 28. Chen Y, Bao B, Lv Y et al. Nab-paclitaxel-based regimens with docetaxel-based regimens as neoadjuvant treatment for early breast cancer. Invest. New Drugs 39(2), 524–529 (2021).
  Medline CASGoogle Scholar
• 29. Yoneshima Y, Morita S, Ando M et al. Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC. J. Thorac. Oncol. 16(9), 1523–1532 (2021).
  Medline CASGoogle Scholar
• 30. Socinski MA, Bondarenko I, Karaseva NA et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J. Clin. Oncol. 30(17), 2055–2062 (2012). • Randomized phase III trial evaluating the efficacy of nab-paclitaxel in non-small-cell lung cancer.
  Medline CASGoogle Scholar
• 31. Wu Y, Feng J, Hu W, Luo Q. A randomized placebo-controlled clinical study of nab-paclitaxel as second-line chemotherapy for patients with advanced non-small cell lung cancer in China. Biosci. Rep. 37(4), BSR20170020 (2017).
  Medline CASGoogle Scholar
• 32. Sakata S, Saeki S, Okamoto I et al. Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto Thoracic Oncology Study Group (KTOSG) trial 1301. Lung Cancer 99, 41–45 (2016).
  MedlineGoogle Scholar
• 33. Tanaka H, Taima K, Morimoto T et al. A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer. BMC Cancer 17(1), 683 (2017).
  MedlineGoogle Scholar